

Supporting Information For:

An Efficient Synthesis of γ -Hydroxy- α,β -unsaturated Aldehydic Esters of 2-Lysophosphatidylcholine

*Jaewoo Choi, James M. Laird and Robert G. Salomon**

Department of Chemistry, Case Western Reserve University, Cleveland, Ohio 44106-7078

Contents

Title	S1
Contents	S2
General methods	S4
¹ H NMR (CDCl ₃) spectrum of Ethyl (<i>E</i>)-4,7-dioxohept-5-enoate (8)	S5
¹³ C NMR (CDCl ₃) spectrum of Ethyl (<i>E</i>)-4,7-dioxohept-5-enoate (8)	S5
¹ H NMR (CDCl ₃) spectrum of Ethyl (<i>E</i>)-7,7-dimethoxy-4-oxohept-5-enoate (9)	S6
¹³ C NMR (CDCl ₃) spectrum of Ethyl (<i>E</i>)-7,7-dimethoxy-4-oxohept-5-enoate (9)	S6
¹ H NMR (CDCl ₃) spectrum of Ethyl (<i>E</i>)-4-hydroxy-7,7-dimethoxyhept-5-enoate (10)	S7
¹ H NMR (CDCl ₃) spectrum of Ethyl (<i>E</i>)-4-hydroxy-7,7-dimethoxyhept-5-enoate (11)	S7
gCOSY NMR (CDCl ₃) spectrum of Ethyl (<i>E</i>)-4-hydroxy-7,7-dimethoxyhept-5-enoate (11)	S8
¹ H NMR (CDCl ₃) spectrum of (<i>E</i>)-3-(5-oxotetrahydrofuran-2-yl)acrylaldehyde (12)	S8
¹ H NMR (CDCl ₃) spectrum of (<i>E</i>)-7,7-dimethoxy-4-oxohept-5-enoic acid (3a)	S9
¹³ C NMR (CDCl ₃) spectrum of (<i>E</i>)-7,7-dimethoxy-4-oxohept-5-enoic acid (3a)	S9
¹ H NMR (CD ₃ OD+CDCl ₃) spectrum of (<i>E</i>)-(7,7-dimethoxy-4-oxohept-5-enoyl)-1-palmitoyl- <i>sn</i> -glycero-3-phosphatidylcholine (18a)	S10
¹³ C NMR (CD ₃ OD+CDCl ₃) spectrum of (<i>E</i>)-(7,7-dimethoxy-4-oxohept-5-enoyl)-1-palmitoyl- <i>sn</i> -glycero-3-phosphatidylcholine (18a)	S10
¹ H NMR (CD ₃ OD+CDCl ₃) spectrum of (<i>E</i>)-(4-hydroxy-7,7-dimethoxyhept-5-enoyl)-1-palmitoyl- <i>sn</i> -glycero-3-phosphatidylcholine (2a)	S11
¹³ C NMR (CD ₃ OD+CDCl ₃) spectrum of (<i>E</i>)-(4-hydroxy-7,7-dimethoxyhept-5-enoyl)-1-palmitoyl- <i>sn</i> -glycero-3-phosphatidylcholine (2a)	S11
¹ H NMR (CD ₃ OD+CDCl ₃) spectrum of (<i>E</i>)-(4-hydroxy-7-oxohept-5-enoyl)-1-palmitoyl- <i>sn</i> -glycero-3-phosphatidylcholine (HOHA-PC, 1a)	S12
¹ H NMR (CDCl ₃) spectrum of 1-tributylstannyl-3,3-diethoxy-prop-1-ene (4)	S12
¹ H NMR (CDCl ₃) spectrum of Methyl (<i>E</i>)-8,8-diethoxy-5-oxooct-6-enoate (14b)	S13
¹³ C NMR (CDCl ₃) spectrum of Methyl (<i>E</i>)-8,8-diethoxy-5-oxooct-6-enoate (14b)	S13
¹ H NMR (CDCl ₃) spectrum of Methyl (<i>E</i>)-8,8-diethoxy-5-hydroxyoct-6-enoate (15b)	S14
gCOSY (CDCl ₃) spectrum of Methyl (<i>E</i>)-8,8-diethoxy-5-hydroxyoct-6-enoate (15b)	S14
¹ H NMR (CDCl ₃) spectrum of Methyl (<i>E</i>)-5-hydroxy-8-oxooct-6-enoate (16)	S15

gCOSY NMR (CDCl ₃) spectrum of Methyl (<i>E</i>)-5-hydroxy-8-oxooct-6-enoate (16)	S15
¹ H NMR (CDCl ₃) spectrum of (<i>E</i>)-3-(6-oxotetrahydro-2H-pyran-2-yl)acrylaldehyde (17)	S16
¹ H NMR (CDCl ₃) spectrum of (<i>E</i>)-8,8-diethoxy-5-oxooct-6-enoic acid (3b)	S16
¹³ C NMR (CDCl ₃) spectrum of (<i>E</i>)-8,8-diethoxy-5-oxooct-6-enoic acid (3b)	S17
¹ H NMR (CD ₃ OD+CDCl ₃) spectrum of (<i>E</i>)-(8,8-diethoxy-5-oxooct-6-enoyl)-1-palmitoyl- <i>sn</i> -glycero-3-phosphatidylcholine (18b)	S17
¹³ C NMR (CD ₃ OD+CDCl ₃) spectrum of (<i>E</i>)-(8,8-diethoxy-5-oxooct-6-enoyl)-1-palmitoyl- <i>sn</i> -glycero-3-phosphatidylcholine (18b)	S18
¹ H NMR (CD ₃ OD+CDCl ₃) spectrum of (<i>E</i>)-(5-hydroxy-8,8-diethoxyoct-6-enoyl)-1-palmitoyl- <i>sn</i> -glycero-3-phosphatidylcholine (2b)	S18
¹³ C NMR (CD ₃ OD+CDCl ₃) spectrum of (<i>E</i>)-(5-hydroxy-8,8-diethoxyoct-6-enoyl)-1-palmitoyl- <i>sn</i> -glycero-3-phosphatidylcholine (2b)	S19
¹ H NMR (CD ₃ OD+CDCl ₃) spectrum of (<i>E</i>)-(5-hydroxy-8-oxooct-6-enoyl)-1-palmitoyl- <i>sn</i> -glycero-3-phosphatidylcholine (HOOA-PC, 1b)	S19
¹ H NMR (CD ₃ OD+CDCl ₃) spectrum of Methyl-9-(chlorocarbonyl)octanoate (7b)	S20
IR spectrum of Methyl-9-(chlorocarbonyl)octanoate (5c)	S20
¹ H NMR (CDCl ₃) spectrum of Methyl (<i>E</i>)-12,12-diethoxy-9-oxodec-10-enoate (14c)	S21
¹³ C NMR (CDCl ₃) spectrum of Methyl (<i>E</i>)-12,12-diethoxy-9-oxodec-10-enoate (14c)	S21
¹ H NMR (CDCl ₃) spectrum of (<i>E</i>)-12,12-diethoxy-9-oxodec-10-enoic acid (3c)	S22
¹³ C NMR (CDCl ₃) spectrum of (<i>E</i>)-12,12-diethoxy-9-oxodec-10-enoic acid (3c)	S22
¹ H NMR (CD ₃ OD+CDCl ₃) spectrum of (<i>E</i>)-(12,12-diethoxy-9-oxodec-10-enoyl)-1-palmitoyl- <i>sn</i> -glycero-3-phosphatidylcholine (18c)	S23
¹³ C NMR (CD ₃ OD+CDCl ₃) spectrum of (<i>E</i>)-(12,12-diethoxy-9-oxodec-10-enoyl)-1-palmitoyl- <i>sn</i> -glycero-3-phosphatidylcholine (18c)	S23
¹ H NMR (CD ₃ OD+CDCl ₃) spectrum of (<i>E</i>)-(9-hydroxy-12,12-diethoxydec-10-enoyl)-1-palmitoyl- <i>sn</i> -glycero-3-phosphatidylcholine (2c)	S24
¹ H NMR (CD ₃ OD+CDCl ₃) spectrum of (<i>E</i>)-(9-hydroxy-12,12-diethoxydec-10-enoyl)-1-palmitoyl- <i>sn</i> -glycero-3-phosphatidylcholine (2c)	S24
¹ H NMR (CD ₃ OD+CDCl ₃) spectrum of (<i>E</i>)-(9-hydroxy-12-oxodec-10-enoyl)-1-palmitoyl- <i>sn</i> -glycero-3-phosphatidylcholine (HODA-PC, 1c)	S25

General methods.

Proton magnetic resonance (^1H NMR) spectra and carbon magnetic resonance (^{13}C NMR) spectra were recorded on a Varian Inova AS400 spectrometer operating 400 MHz or 75 MHz. Proton chemical shifts are reported in parts per million (ppm) on δ scale relative to CDCl_3 (δ 7.26) or CD_3OD (δ 3.31). ^1H NMR spectral data are tabulated in terms of multiplicity of proton absorption (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad), coupling constants (Hz), number of protons. gCOSY experiment was done on a spectrometer at 400 MHz. All high resolution mass spectra were recorded on a Kratos AEI MS25 RFA high resolution mass spectrometer at 20 eV. FT-IR was obtained as KBr pellets using an MIDAC Co. M2000. All solvents were distilled under a nitrogen atmosphere prior to use, and all materials were obtained from Aldrich unless specified. Flash chromatography was performed with ACS grade solvent. R_f values are quoted for TLC plates of thickness 0.25 mm. The plates were visualized with iodine, dinitrophenylhydrazine or phosphomolybdic acid reagents. Flash column chromatograph was performed on 230-400 mesh silica gels supplied by Whatman and Sorbent.




Figure S1 The 400MHz ¹H NMR (CDCl₃) spectrum of Ethyl (*E*)-4,7-dioxohept-5-enoate (**8**)




Figure S2 The 100MHz ¹³C NMR (CDCl₃) spectrum of Ethyl (*E*)-4,7-dioxohept-5-enoate (**8**)




Figure S3 The 400MHz ¹H NMR (CDCl₃) spectrum of Ethyl (*E*)-7,7-dimethoxy-4-oxohept-5-enoate (**9**)




Figure S4 The 100MHz ¹³C NMR (CDCl₃) spectrum of Ethyl (*E*)-7,7-dimethoxy-4-oxohept-5-enoate (**9**)




Figure S5 The 400MHz ¹H NMR (CDCl₃) spectrum of Ethyl (*E*)-4-hydroxy-7,7-dimethoxyhept-5-enoate (**10**)




Figure S6 The 400MHz ¹H NMR (CDCl₃) spectrum of Ethyl (*E*)-4-hydroxy-7,7-dimethoxyhept-5-enoate (**11**)




Figure S7 The 400MHz gCOSY NMR (CDCl₃) spectrum of Ethyl (*E*)-4-hydroxy-7,7-dimethoxyhept-5-enoate (**11**)




Figure S8 The 400MHz ¹H NMR (CDCl₃) spectrum of (*E*)-3-(5-oxotetrahydrofuran-2-yl)acrylaldehyde (**12**)




Figure S9 The 400MHz ¹H NMR (CDCl₃) spectrum of (*E*)-7,7-dimethoxy-4-oxohept-5-enoic acid (**3a**)




Figure S10 The 100MHz ¹³C NMR (CDCl₃) spectrum of (*E*)-7,7-dimethoxy-4-oxohept-5-enoic acid (**3a**)




Figure S11 The 400MHz ^1H NMR ($\text{CD}_3\text{OD}+\text{CDCl}_3$) spectrum of (*E*)-(7,7-dimethoxy-4-oxohept-5-enoyl)-1-palmitoyl-*sn*-glycero-3-phosphatidylcholine (**18a**)




Figure S12 The 100MHz ^{13}C NMR ($\text{CD}_3\text{OD}+\text{CDCl}_3$) spectrum of (*E*)-(7,7-dimethoxy-4-oxohept-5-enoyl)-1-palmitoyl-*sn*-glycero-3-phosphatidylcholine (**18a**)




Figure S13 The 400MHz ¹H NMR (CD₃OD+CDCl₃) spectrum of (*E*)-(4-hydroxy-7,7-dimethoxyhept-5-enoyl)-1-palmitoyl-*sn*-glycero-3-phosphatidylcholine (**2a**)




Figure S14 The 100MHz ¹³C NMR (CD₃OD+CDCl₃) spectrum of (*E*)-(4-hydroxy-7,7-dimethoxyhept-5-enoyl)-1-palmitoyl-*sn*-glycero-3-phosphatidylcholine (**2a**)




Figure S15 The 400MHz ^1H NMR ($\text{CD}_3\text{OD}+\text{CDCl}_3$) spectrum of (*E*)-(4-hydroxy-7-oxohept-5-enoyl)-1-palmitoyl-*sn*-glycero-3-phosphatidylcholine (**HOHA-PC, 1a**)




Figure S16 The 400MHz ^1H NMR (CDCl_3) spectrum of 1-tributylstannyl-3,3-diethoxy-prop-1-ene (**4**)




Figure S17 The 400MHz ¹H NMR (CDCl₃) spectrum of Methyl (*E*)-8,8-diethoxy-5-oxooct-6-enoate (**14b**)




Figure S18 The 100MHz ¹³C NMR (CDCl₃) spectrum of Methyl (*E*)-8,8-diethoxy-5-oxooct-6-enoate (**14b**)




Figure S19 The 400MHz ^1H NMR (CDCl_3) spectrum of Methyl (*E*)-8,8-diethoxy-5-hydroxyoct-6-enoate (15b)




Figure S20 The 400MHz gCOSY (CDCl₃) spectrum of Methyl (*E*)-8,8-diethoxy-5-hydroxyoct-6-enoate (**15b**)




Figure S21 The 400MHz ¹H NMR (CDCl₃) spectrum of (*E*)-methyl-5-hydroxy-8-oxooct-6-enoate (**16**)




Figure S22 The 400MHz gCOSY NMR (CDCl₃) spectrum of (*E*)-methyl-5-hydroxy-8-oxooct-6-enoate (**16**)




Figure S23 The 400MHz ¹H NMR (CDCl₃) spectrum of (*E*)-3-(6-oxotetrahydro-2H-pyran-2-yl)acrylaldehyde (**17**)




Figure S24 The 400MHz ^1H NMR (CDCl_3) spectrum of (*E*)-8,8-diethoxy-5-oxooct-6-enoic acid (**3b**)




Figure S25 The 100MHz ^{13}C NMR (CDCl_3) spectrum of (*E*)-8,8-diethoxy-5-oxooct-6-enoic acid (**3b**)




Figure S26 The 400MHz ^1H NMR ($\text{CD}_3\text{OD}+\text{CDCl}_3$) spectrum of (*E*)-(8,8-diethoxy-5-oxooct-6-enoyl)-1-palmitoyl-*sn*-glycero-3-phosphatidylcholine (**18b**)




Figure S27 The 100MHz ^{13}C NMR ($\text{CD}_3\text{OD}+\text{CDCl}_3$) spectrum of (*E*)-(8,8-diethoxy-5-oxooct-6-enoyl)-1-palmitoyl-*sn*-glycero-3-phosphatidylcholine (**18b**)




Figure S28 The 400MHz ^1H NMR ($\text{CD}_3\text{OD}+\text{CDCl}_3$) spectrum of (*E*)-(5-hydroxy-8,8-diethoxyoct-6-enoyl)-1-palmitoyl-*sn*-glycero-3-phosphatidylcholine (**2b**)




Figure S29 The 100MHz ^{13}C NMR ($\text{CD}_3\text{OD}+\text{CDCl}_3$) spectrum of (*E*)-(5-hydroxy-8,8-diethoxyoct-6-enoyl)-1-palmitoyl-*sn*-glycero-3-phosphatidylcholine (**2b**)




Figure S30 The 400MHz ^1H NMR ($\text{CD}_3\text{OD}+\text{CDCl}_3$) spectrum of (*E*)-(5-hydroxy-8-oxooct-6-enoyl)-1-palmitoyl-*sn*-glycero-3-phosphatidylcholine (**HOOA-PC, 1b**)




Figure S31 The 400MHz ^1H NMR ($\text{CD}_3\text{OD}+\text{CDCl}_3$) spectrum of Methyl-9-(chlorocarbonyl)octanoate (**7b**)




Figure S32 The IR spectrum of Methyl-9-(chlorocarbonyl)octanoate (**7b**)




Figure S33 The 400MHz ¹H NMR (CDCl₃) spectrum of Methyl (*E*)-12,12-diethoxy-9-oxodec-10-enoate (**14c**)




Figure S34 The 100MHz ^{13}C NMR (CDCl_3) spectrum of Methyl (*E*)-12,12-diethoxy-9-oxodec-10-enoate (**14c**)




Figure S35 The 400MHz ^1H NMR (CDCl_3) spectrum of (*E*)-12,12-diethoxy-9-oxodec-10-enoic acid (**3c**)




Figure S36 The 100MHz ^{13}C NMR (CDCl_3) spectrum of (*E*)-12,12-diethoxy-9-oxodec-10-enoic acid (**3c**)




Figure S37 The 400MHz ^1H NMR ($\text{CD}_3\text{OD}+\text{CDCl}_3$) spectrum of (*E*)-(12,12-diethoxy-9-oxodec-10-enoyl)-1-palmitoyl-*sn*-glycero-3-phosphatidylcholine (**18c**)




Figure S38 The 100MHz ^{13}C NMR ($\text{CD}_3\text{OD}+\text{CDCl}_3$) spectrum of (*E*)-(12,12-diethoxy-9-oxodec-10-enoyl)-1-palmitoyl-*sn*-glycero-3-phosphatidylcholine (**18c**)




Figure S39 The 400MHz ^1H NMR ($\text{CD}_3\text{OD}+\text{CDCl}_3$) spectrum of (*E*)-(9-hydroxy-12,12-diethoxydec-10-enoyl)-1-palmitoyl-*sn*-glycero-3-phosphatidylcholine (**2c**)




Figure S40 The 400MHz ^1H NMR ($\text{CD}_3\text{OD}+\text{CDCl}_3$) spectrum of (*E*)-(9-hydroxy-12,12-diethoxydec-10-enoyl)-1-palmitoyl-*sn*-glycero-3-phosphatidylcholine (**2c**)




Figure S41 The 400MHz ^1H NMR ($\text{CD}_3\text{OD}+\text{CDCl}_3$) spectrum of (*E*)-(9-hydroxy-12-oxodec-10-enoyl)-1-palmitoyl-*sn*-glycero-3-phosphatidylcholine (**HODA-PC, 1c**)